ADPKD Diagnostik & Therapie Standard 2022 - Prof. Dr. Roman-Ulrich Müller, Köln

Prof. Dr. Roman-Ulrich Müller erläutert Diagnostik und Therapie der Autosomal-dominanten polyzystischen Nierenerkrankung („Autosomal dominant polycystic kidney disease“; ADPKD).
Prof. Dr. Müller ist Internist, Nephrologe und Leiter des Schwerpunktes „Diagnostik und Therapie ADPKD“ an der Uniklinik Köln. Prof. Dr. Müller initiierte mehrere klinische Studien zur Progressionshemmung der ADPKD, und er ist Erstautor aktueller interdisziplinärer Konsensusleitlinien zum Einsatz von Tolvaptan bei ADPKD.
Das Gespräch wurde am 25.05.2022 geführt. Moderatoren: Priv.-Doz. Dr. Andreas Kronbichler (Cambridge, UK und Innsbruck, Österreich), Dr. Insa Emrich (Homburg) und Prof. Dr. Gunnar Heine (Frankfurt am Main).
Weitere Literatur:
MO016: Feasibility and Effectiveness of Short-Term Ketogenic Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD): Results from the Reset-Pkd Study
Simon Oehm, Konstantin Steinke, Sita Arjune, Polina Todorova, Christoph Lindemann, Fabian Woestmann, Franziska Meyer, Florian Siedek, Thomas Weimbs, Franziska Grundmann, Roman-Ulrich Mueller
Nephrology Dialysis Transplantation Supplement 3 doi.org/10.1093/ndt/gfac061.011
Management of autosomal-dominant polycystic kidney disease-state-of-the-art.
Müller RU, Benzing T.
Clin Kidney J. 2018 doi: 10.1093/ckj/sfy103
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.
N Engl J Med. 2012 doi: 10.1056/NEJMoa1205511
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E et al.; DIPAK-1 Investigators.
JAMA. 2018 doi: 10.1001/jama.2018.15870.
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators.
Gastroenterology. 2019 doi: 10.1053/j.gastro.2019.04.018
Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
Kramers BJ, Koorevaar IW, van Gastel MDA, van Goor H, Hallows KR, Heerspink HL, Li H, Leonhard WN, Peters DJM, Qiu J, Touw DJ, Gansevoort RT, Meijer E.
Clin J Am Soc Nephrol. 2022 doi: 10.2215/CJN.11260821.
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
Caroli A et al.; ALADIN study group.
Lancet. 2013 doi: 10.1016/S0140-6736(13)61407-5
Polycystic kidney disease.
Bergmann C et al.
Nat Rev Dis Primers. 2018 doi: 10.1038/s41572-018-0047-y
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
Irazabal MV et al.; CRISP Investigators.
J Am Soc Nephrol. 2015 doi: 10.1681/ASN.2013101138
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
Müller RU et al.
Nephrol Dial Transplant. 2022 doi: 10.1093/ndt/gfab312.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE et al.; REPRISE Trial Investigators.
N Engl J Med. 2017 doi: 10.1056/NEJMoa1710030.
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
Torres VE et al.
Kidney Int. 2017 doi: 10.1016/j.kint.2016.10.018.
Polycystic kidney disease. Bergmann C et al.
Nat Rev Dis Primers. 2018 doi: 10.1038/s41572-018-0047-y
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
Torres VE et al.; HALT-PKD Trial Investigators.
N Engl J Med. 2014 doi: 10.1056/NEJMoa1402686
Prescribed Water Intake in Autosomal Dominant
Polycystic Kidney Disease
Rangan GK et al.
NEJM Evid 2022 DOI: 10.1056/EVIDoa2100021
Blood pressure in early autosomal dominant polycystic kidney disease.
Schrier RW et al.; HALT-PKD Trial Investigators.
N Engl J Med. 2014 doi: 10.1056/NEJMoa1402685